Lilly, BI approach CV-benefit label change for SGLT2 med Jardiance

Eli Lilly ($LLY) and Boehringer Ingelheim are one step closer to an important label change for SGLT2 contender Jardiance. The FDA has accepted a supplemental New Drug Application that, if approved, will allow reps to tout study data showing the med can cut cardiovascular risks in Type 2 diabetes patients. More from FiercePharmaMarketing